216 related articles for article (PubMed ID: 33713320)
1. Integrated Gene Expression and Methylation Analyses Identify DLL3 as a Biomarker for Prognosis of Malignant Glioma.
Maimaiti A; Wang X; Hao Y; Jiang L; Shi X; Pei Y; Feng Z; Kasimu M
J Mol Neurosci; 2021 Aug; 71(8):1622-1635. PubMed ID: 33713320
[TBL] [Abstract][Full Text] [Related]
2. DLL3 expression and methylation are associated with lower-grade glioma immune microenvironment and prognosis.
Noor H; Whittaker S; McDonald KL
Genomics; 2022 Mar; 114(2):110289. PubMed ID: 35124175
[TBL] [Abstract][Full Text] [Related]
3. [Single-cell transcriptome analysis of multigrade glioma heterogeneity and immune microenvironment revealed potential prognostic biomarkers].
Liu J; Xu K; Ma L; Wang Y
Sheng Wu Gong Cheng Xue Bao; 2022 Oct; 38(10):3790-3808. PubMed ID: 36305410
[TBL] [Abstract][Full Text] [Related]
4. Serine Incorporator 2 (SERINC2) Expression Predicts an Unfavorable Prognosis of Low-Grade Glioma (LGG): Evidence from Bioinformatics Analysis.
Qi C; Lei L; Hu J; Wang G; Liu J; Ou S
J Mol Neurosci; 2020 Oct; 70(10):1521-1532. PubMed ID: 32642801
[TBL] [Abstract][Full Text] [Related]
5. CKS2 (CDC28 protein kinase regulatory subunit 2) is a prognostic biomarker in lower grade glioma: a study based on bioinformatic analysis and immunohistochemistry.
Hu M; Li Z; Qiu J; Zhang R; Feng J; Hu G; Ren J
Bioengineered; 2021 Dec; 12(1):5996-6009. PubMed ID: 34494924
[TBL] [Abstract][Full Text] [Related]
6. Association between small heat shock protein B11 and the prognostic value of MGMT promoter methylation in patients with high-grade glioma.
Cheng W; Li M; Jiang Y; Zhang C; Cai J; Wang K; Wu A
J Neurosurg; 2016 Jul; 125(1):7-16. PubMed ID: 26544773
[TBL] [Abstract][Full Text] [Related]
7. Elevated TYROBP expression predicts poor prognosis and high tumor immune infiltration in patients with low-grade glioma.
Lu J; Peng Y; Huang R; Feng Z; Fan Y; Wang H; Zeng Z; Ji Y; Wang Y; Wang Z
BMC Cancer; 2021 Jun; 21(1):723. PubMed ID: 34162355
[TBL] [Abstract][Full Text] [Related]
8. Cell Surface Notch Ligand DLL3 is a Therapeutic Target in Isocitrate Dehydrogenase-mutant Glioma.
Spino M; Kurz SC; Chiriboga L; Serrano J; Zeck B; Sen N; Patel S; Shen G; Vasudevaraja V; Tsirigos A; Suryadevara CM; Frenster JD; Tateishi K; Wakimoto H; Jain R; Riina HA; Nicolaides TP; Sulman EP; Cahill DP; Golfinos JG; Isse K; Saunders LR; Zagzag D; Placantonakis DG; Snuderl M; Chi AS
Clin Cancer Res; 2019 Feb; 25(4):1261-1271. PubMed ID: 30397180
[TBL] [Abstract][Full Text] [Related]
9. Identification of a robust biomarker LAPTM4A for glioma based on comprehensive computational biology and experimental verification.
Ding Y; Jiang Y; Zeng H; Zhou M; Zhou X; Yu Z; Pan J; Geng X; Zhu Y; Zheng H; Huang S; Gong Y; Huang H; Xiong C; Huang D
Aging (Albany NY); 2024 Apr; 16(8):6954-6989. PubMed ID: 38613802
[TBL] [Abstract][Full Text] [Related]
10. Investigation of Candidate Genes and Pathways in Basal/TNBC Patients by Integrated Analysis.
Liu Q; Song X; Liu Z; Yu Z
Technol Cancer Res Treat; 2021; 20():15330338211019506. PubMed ID: 34184566
[TBL] [Abstract][Full Text] [Related]
11. SYT16 is a prognostic biomarker and correlated with immune infiltrates in glioma: A study based on TCGA data.
Chen J; Wang Z; Wang W; Ren S; Xue J; Zhong L; Jiang T; Wei H; Zhang C
Int Immunopharmacol; 2020 Jul; 84():106490. PubMed ID: 32289666
[TBL] [Abstract][Full Text] [Related]
12. In silico identification of the prognostic biomarkers and therapeutic targets associated with cancer stem cell characteristics of glioma.
Lvu W; Fei X; Chen C; Zhang B
Biosci Rep; 2020 Aug; 40(8):. PubMed ID: 32725165
[TBL] [Abstract][Full Text] [Related]
13. A Novel 10-Gene Signature Predicts Poor Prognosis in Low Grade Glioma.
Liu W; Zou J; Ren R; Liu J; Zhang G; Wang M
Technol Cancer Res Treat; 2021; 20():1533033821992084. PubMed ID: 33550903
[TBL] [Abstract][Full Text] [Related]
14. Bioinformatic Profiling Identifies a Glucose-Related Risk Signature for the Malignancy of Glioma and the Survival of Patients.
Zhao S; Cai J; Li J; Bao G; Li D; Li Y; Zhai X; Jiang C; Fan L
Mol Neurobiol; 2017 Dec; 54(10):8203-8210. PubMed ID: 27900679
[TBL] [Abstract][Full Text] [Related]
15. ABCD3 is a prognostic biomarker for glioma and associated with immune infiltration: A study based on oncolysis of gliomas.
Li J; Zhang Y; Qu Z; Ding R; Yin X
Front Cell Infect Microbiol; 2022; 12():956801. PubMed ID: 35959373
[TBL] [Abstract][Full Text] [Related]
16. Grade II/III Glioma Microenvironment Mining and Its Prognostic Merit.
Chen J; Hou C; Wang P; Yang Y; Zhou D
World Neurosurg; 2019 Dec; 132():e76-e88. PubMed ID: 31518750
[TBL] [Abstract][Full Text] [Related]
17. ARL3 is downregulated and acts as a prognostic biomarker in glioma.
Wang Y; Zhao W; Liu X; Guan G; Zhuang M
J Transl Med; 2019 Jun; 17(1):210. PubMed ID: 31234870
[TBL] [Abstract][Full Text] [Related]
18. Selenoprotein GPX1 is a prognostic and chemotherapy-related biomarker for brain lower grade glioma.
Chen X; Fu G; Li L; Zhao Q; Ke Z; Zhang R
J Trace Elem Med Biol; 2022 Dec; 74():127082. PubMed ID: 36155420
[TBL] [Abstract][Full Text] [Related]
19. An Immune-Related Signature for Predicting the Prognosis of Lower-Grade Gliomas.
Zhang H; Li X; Li Y; Chen B; Zong Z; Shen L
Front Immunol; 2020; 11():603341. PubMed ID: 33363544
[TBL] [Abstract][Full Text] [Related]
20. A nuclear transport-related gene signature combined with IDH mutation and 1p/19q codeletion better predicts the prognosis of glioma patients.
Zhu Z; Lan Y; Wang L; Ge J; Wang J; Liu F; He Z; Zhang H; Luo M; Lin D; Tan Y; Xu Y; Luo T
BMC Cancer; 2020 Nov; 20(1):1072. PubMed ID: 33167941
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
